3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
117
Triple Negative Breast Neoplasms
45
Neoplasm Metastasis
11
Pancreatic Neoplasms
8
Inflammatory Breast Neoplasms
7
Breast Neoplasms, Male
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Ovarian Neoplasms
6
Carcinoma, Non-Small-Cell Lung
5
Stomach Neoplasms
4
Neoplasms
4
Lung Neoplasms
4
Carcinoma, Ductal, Breast
4
Sarcoma
3
Prostatic Neoplasms
3
Lymphoma, Non-Hodgkin
3
Endometrial Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Hepatocellular
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Hodgkin Disease
2
Esophageal Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Advanced Breast Cancer
2
Thrombocytosis
1
Stages II-III Breast Cancer
1
Primary Myelofibrosis
1
Interventions
Trastuzumab
5
Carboplatin
5
Docetaxel
4
pertuzumab
3
Paclitaxel
3
Cyclophosphamide
3
pembrolizumab
2
Epirubicin
2
Doxorubicin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
taxane
1
talazoparib
1
sarilumab
1
pyrotinib
1
pirarubicin
1
pexidartinib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Albumin-Bound Paclitaxel
×
Breast
×
Clear all
NCT01830244
2017-07-02
Neonab
Barwon Health
Phase 2
Unknown
60 enrolled